Metabolic alterations of peripheral blood immune cells and heterogeneity of neutrophil in intracranial aneurysms patients

Abstract

Background: Intracranial aneurysms (IAs) represent a severe cerebrovascular disease that can potentially lead to subarachnoid haemorrhage. Previous studies have demonstrated the involvement of peripheral immune cells in the formation and progression of IAs. Nevertheless, the impact of metabolic alterations in peripheral immune cells and changes in neutrophil heterogeneity on the occurrence and progression of IAs remains uncertain.

Methods: Single-cell Cytometry by Time-of-Flight (CyTOF) technology was employed to profile the single-cell atlas of peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs) in 72 patients with IAs. In a matched cohort, metabolic shifts in PBMC subsets of IA patients were investigated by contrasting the expression levels of key metabolic enzymes with their respective counterparts in the healthy control group. Simultaneously, compositional differences in peripheral blood PMNs subsets between the two groups were analysed to explore the impact of altered heterogeneity in neutrophils on the initiation and progression of IAs. Furthermore, integrating immune features based on CyTOF analysis and clinical characteristics, we constructed an aneurysm occurrence model and an aneurysm growth model using the random forest method in conjunction with LASSO regression.

Results: Different subsets exhibited distinct metabolic characteristics. Overall, PBMCs from patients elevated CD98 expression and increased proliferation. Conversely, CD36 was up-regulated in T cells, B cells and monocytes from the controls but down-regulated in NK and NKT cells. The comparison also revealed differences in the metabolism and function of specific subsets between the two groups. In terms of PMNs, the neutrophil landscape within patients group revealed a pronounced shift towards heightened complexity. Various neutrophil subsets from the IA group generally exhibited lower expression levels of anti-inflammatory functional molecules (IL-4 and IL-10). By integrating clinical and immune features, the constructed aneurysm occurrence model could precisely identify patients with IAs with high prediction accuracy (AUC = 0.987). Furthermore, the aneurysm growth model also exhibited superiority over ELAPSS scores in predicting aneurysm growth (lower prediction errors and out-of-bag errors).

Conclusion: These findings enhanced our understanding of peripheral immune cell participation in aneurysm formation and growth from the perspectives of immune metabolism and neutrophil heterogeneity. Moreover, the predictive model based on CyTOF features holds the potential to aid in diagnosing and monitoring the progression of human IAs.

Keywords

CyTOF / heterogeneity of neutrophils / immune metabolism / intracranial aneurysms

References

[1] Schievink WI. Intracranial aneurysms. N Engl J Med. 1997;336(1):28-40.

[2] Malhotra A, Wu X, Forman HP, et al. Growth and rupture risk of small unruptured intracranial aneurysms: a systematic review. Ann Intern Med. 2017;167(1):26-33.

[3] Tawk RG, Hasan TF, D'Souza CE, Peel JB, Freeman WD. Diagnosis and treatment of unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage. Mayo Clin Proc. 2021;96(7):1970-2000.

[4] Alfano JM, Kolega J, Natarajan SK, et al. Intracranial aneurysms occur more frequently at bifurcation sites that typically experience higher hemodynamic stresses. Neurosurgery. 2013;73(3):497-505.

[5] Gruszka W, Zbroszczyk M, Komenda J, Gruszczyńska K, Baron J. The role of inflammation and potential pharmacological therapy in intracranial aneurysms. Neurol Neurochir Pol. 2018;52(6):662-669.

[6] Matur AV, Yamani AS, Robinson MW, et al. Association between underlying autoimmune disease and small aneurysm size at rupture. J Neurosurg. 2023;138(3):701-708.

[7] Guimarães F, Duque C. Neuro-Behçet disease manifesting as multiple cerebral aneurysms. Neurology. 2021;97(4):191-192.

[8] Liu K, Sun J, Shao L, et al. Correlation of periodontal diseases with intracranial aneurysm formation: novel predictive indicators. Chin Neurosurg J. 2021;7(1):31.

[9] Ge P, Li H, Ya X, et al. Single-cell atlas reveals different immune environments between stable and vulnerable atherosclerotic plaques. Front Immunol. 2022;13:1085468.

[10] Artyomov MN, Van den Bossche J. Immunometabolism in the single-cell era. Cell Metab. 2020;32(5):710-725.

[11] Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570-586.

[12] Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.

[13] Ganeshan K, Chawla A. Metabolic regulation of immune responses. Annu Rev Immunol. 2014;32:609-634.

[14] Chapman NM, Chi H. Metabolic adaptation of lymphocytes in immunity and disease. Immunity. 2022;55(1):14-30.

[15] Zhang B, Qin Y, Zhao S, et al. Association of elevated neutrophil-to-lymphocyte ratio with increased intracranial aneurysm stability scores and aneurysm growth. J Stroke Cerebrovasc Dis. 2023;32(4):107052.

[16] Kawabata S, Takagaki M, Nakamura H, et al. Dysbiosis of gut microbiome is associated with rupture of cerebral aneurysms. Stroke. 2022;53(3):895-903.

[17] Tutino VM, Poppenberg KE, Jiang K, et al. Circulating neutrophil transcriptome may reveal intracranial aneurysm signature. PLoS One. 2018;13(1):e0191407.

[18] Xie X, Shi Q, Wu P, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol. 2020;21(9):1119-1133.

[19] Sas AR, Carbajal KS, Jerome AD, et al. A new neutrophil subset promotes CNS neuron survival and axon regeneration. Nat Immunol. 2020;21(12):1496-1505.

[20] Nolan E, Bridgeman VL, Ombrato L, et al. Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization. Nat Cancer. 2022;3(2):173-187.

[21] Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022;19(2):177-191.

[22] Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell. 2016;165(4):780-791.

[23] Hartmann FJ, Mrdjen D, McCaffrey E, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021;39(2):186-197.

[24] Mukhopadhyay M. Metabolic profiling of CD8(+) T cells at the single-cell level. Nat Methods. 2020;17(11):1071.

[25] Qian L, Guo T. Immunometabolism the CyTOF way. Immunity. 2021;54(4):610-613.

[26] Backes D, Rinkel GJE, Greving JP, et al. ELAPSS score for prediction of risk of growth of unruptured intracranial aneurysms. Neurology. 2017;88(17):1600-1606.

[27] Lawton MT, Vates GE. Subarachnoid hemorrhage. N Engl J Med. 2017;377(3):257-266.

[28] Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and preventive management. Nat Rev Neurol. 2016;12(12):699-713.

[29] Brown RD, Broderick JP. Unruptured intracranial aneurysms: epidemiology, natural history, management options, and familial screening. Lancet Neurol. 2014;13(4):393-404.

[30] Edjlali M, Boulouis G, Derraz I, et al. Intracranial aneurysm wall enhancement decreases under anti-inflammatory treatment. Neurology. 2018;91(17):804-805.

[31] Chalouhi N, Ali MS, Jabbour PM, et al. Biology of intracranial aneurysms: role of inflammation. J Cereb Blood Flow Metab. 2012;32(9):1659-1676.

[32] Ge P, Liu C, Chan L, et al. High-dimensional immune profiling by mass cytometry revealed the circulating immune cell landscape in patients with intracranial aneurysm. Front Immunol. 2022;13:922000.

[33] Peng F, Xia J, Niu H, et al. Systemic immune-inflammation index is associated with aneurysmal wall enhancement in unruptured intracranial fusiform aneurysms. Front Immunol. 2023;14:1106459.

[34] Lucke-Wold B, Hosaka K, Dodd W, et al. Interleukin-6: important mediator of vasospasm following subarachnoid hemorrhage. Curr Neurovasc Res. 2021;18(3):364-369.

[35] Ruchika F, Shah S, Delawan M, Durga N, Lucke-Wold B. Cytokines and subarachnoid hemorrhage. In Vitro Diagnosis. 2023;1(1):55.

[36] Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435-449.

[37] Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771-784.

[38] Warren AP, Patel K, McConkey DJ, Palacios R. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood. 1996;87(9):3676-3687.

[39] Bajaj J, Konuma T, Lytle NK, et al. CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. Cancer Cell. 2016;30(5):792-805.

[40] Chen GY, Nuñez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010;10(12):826-837.

[41] Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Network. 2018;18(4):e27.

[42] Marcovecchio PM, Thomas GD, Mikulski Z, et al. Scavenger receptor CD36 directs nonclassical monocyte patrolling along the endothelium during early atherogenesis. Arterioscler Thromb Vasc Biol. 2017;37(11):2043-2052.

[43] Hale JS, Otvos B, Sinyuk M, et al. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014;32(7):1746-1758.

[44] Wang H, Franco F, Tsui YC, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21(3):298-308.

[45] Segherlou ZH, Siyanaki MRH, Lucke-Wold B. Potential effects of adropin in subarachnoid hemorrhage. Neurosci Int. 2023;13(1):12-19.

[46] Gao S, McMillan RP, Jacas J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014;63(10):3242-3252.

[47] Segherlou ZH, Saldarriaga L, Azizi E, et al. MicroRNAs' role in diagnosis and treatment of subarachnoid hemorrhage. Diseases (Basel, Switzerland). 2023;11(2).

[48] Patel CH, Leone RD, Horton MR, Powell JD. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discovery. 2019;18(9):669-688.

[49] McKenna E, Mhaonaigh AU, Wubben R, et al. Neutrophils: need for standardized nomenclature. Front Immunol. 2021;12:602963.

[50] Fukushima K, Nabeshima H, Kida H. Revealing the diversity of neutrophil functions and subsets. Cell Mol Immunol. 2021;18(4):781-783.

[51] Yin M, Zhou HJ, Lin C, et al. CD34(+)KLF4(+) stromal stem cells contribute to endometrial regeneration and repair. Cell Rep. 2019;27(9):2709-2724. e3

[52] Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.

[53] Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.

[54] Rahman S, Sagar D, Hanna RN, et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. 2019;78(7):957-966.

[55] Wang Z, Zhu F, Wang J, et al. Increased CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells correlate with disease severity in systemic lupus erythematosus patients in an iNOS-dependent manner. Front Immunol. 2019;10:1202.

[56] Florez-Pollack S, Tseng LC, Kobayashi M, Hosler GA, Ariizumi K, Chong BF. Expansion of myeloid-derived suppressor cells in the peripheral blood and lesional skin of cutaneous lupus patients. J Invest Dermatol. 2019;139(2):478-481.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.